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Abstract
There is a strong inverse relationship between a females own birth weight and her subsequent risk for gestational diabetes
with increased risk of developing diabetes later in life. We have shown that growth restricted females develop loss of
glucose tolerance during late pregnancy with normal pancreatic function. The aim of this study was to determine whether
growth restricted females develop long-term impairment of metabolic control after an adverse pregnancy adaptation.
Uteroplacental insufficiency was induced by bilateral uterine vessel ligation (Restricted) or sham surgery (Control) in late
pregnancy (E18) in F0 female rats. F1 Control and Restricted female offspring were mated with normal males and allowed to
deliver (termed Ex-Pregnant). Age-matched Control and Restricted Virgins were also studied and glucose tolerance and
insulin secretion were determined. Pancreatic morphology and hepatic glycogen and triacylglycerol content were
quantified respectively. Restricted females were born lighter than Control and remained lighter at all time points studied
(p,0.05). Glucose tolerance, first phase insulin secretion and liver glycogen and triacylglycerol content were not different
across groups, with no changes in b-cell mass. Second phase insulin secretion was reduced in Restricted Virgins (234%,
p,0.05) compared to Control Virgins, suggestive of enhanced peripheral insulin sensitivity but this was lost after pregnancy.
Growth restriction was associated with enhanced basal hepatic insulin sensitivity, which may provide compensatory
benefits to prevent adverse metabolic outcomes often associated with being born small. A prior pregnancy was associated
with reduced hepatic insulin sensitivity with effects more pronounced in Controls than Restricted. Our data suggests that
pregnancy ameliorates the enhanced peripheral insulin sensitivity in growth restricted females and has deleterious effects
for hepatic insulin sensitivity, regardless of maternal birth weight.
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Introduction
Intrauterine growth restriction complicates about 10% of
pregnancies in Western societies and is associated with increased
risk of adult metabolic diseases, including type 2 diabetes, insulin
resistance and dyslipidemia [1,2]. Inadequate uteroplacental
perfusion of oxygen and nutrients to the developing fetus is
responsible for the majority of clinical intrauterine growth
restriction, with a low weight at birth considered a surrogate
marker [1,3]. It has become clear that the susceptibility to develop
features of the metabolic syndrome may be programmed in utero,
attributed to perturbed development of key organs, including
reductions in pancreatic b-cell mass [4–7] and altered liver lipid
metabolism [8,9].
Previously, we have shown that growth restricted male rats
develop impaired glucose tolerance, partly attributed to reduced
pancreatic b-cell mass and insulin secretion and sensitivity in
adulthood [6,7,10]. This is in contrast to growth restricted females
who display normal glucose tolerance despite reductions in basal
insulin concentrations and pancreatic b-cell mass [10–12]. Others
have also reported clear gender dimorphisms, with uteroplacen-
tally restricted male rats developing frank diabetes and obesity
associated with reduced pancreatic b-cell mass and insulin
secretion and sensitivity [4,5]. Females developed fasting hyper-
glycemia and reduced pancreatic function but did not develop
diabetes [13]. In placentally restricted sheep, males but not
females, developed fasting hypoinsulinaemia and impaired glucose
tolerance associated with reduced b-cell mass [14,15]. This
highlights that despite deficits in organ structure and function in
females, they often do not present with a metabolic phenotype.
However, situations of increased insulin demand such as
pregnancy or ageing may reveal an adverse metabolic phenotype
that is not otherwise present in susceptible females born small.
More recently, several studies have shown a strong inverse
relationship between a woman’s own birth weight and her
subsequent risk for gestational diabetes [16–18]. In addition,
women with gestational diabetes have a markedly increased risk of
developing type 2 diabetes in the years following an index
pregnancy, suggesting there are consequences for the mother’s
long term metabolic health [19–21].
Gestational diabetes mellitus is a serious complication of
pregnancy, which carries both short and long term implications
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for both the fetus and the mother [22]. As pregnancy is
characterised by progressive insulin resistance from mid pregnancy
(,50–60% increase), maintenance of normoglycemia requires the
pancreatic b-cells to compensate by appropriately increasing their
insulin secretion. This is can be of great challenge for the
pancreatic islet cells, and as such, it is common for glucose
tolerance to gradually deteriorate during pregnancy [22–24].
Glucose levels do however remain within the normal range for the
majority of pregnant women, while 1–3% develop gestational
diabetes [25]. Furthermore, some years after pregnancy, women
who experienced gestational diabetes continue to exhibit b-cell
dysfunction [24]. Therefore, any degree of abnormal glucose
homeostasis in pregnancy strongly predicts later life development
of type 2 diabetes, which is proportional to the severity of
dysglycemia observed in pregnancy [19–21].
Recently, we have shown that at 4 months of age, virgin growth
restricted females have reduced basal insulin secretion and
pancreatic b-cell mass but normal glucose tolerance [12]. During
late pregnancy however, these growth restricted females developed
impaired glucose tolerance despite normal first and second phase
insulin response and compensatory increases in pancreatic b-cell
mass [12]. We hypothesise that the impaired glucose tolerance that
was demonstrated in late pregnancy in Restricted females would
lead to metabolic dysfunction in later life. Therefore the aim of this
study was to determine whether growth restricted females develop
long term impaired metabolic control (impaired glucose tolerance
and pancreatic dysfunction) following an adverse metabolic
pregnancy adaptation, compared with previously pregnant normal
birth weight females and growth restricted non pregnant female rats.
Methods
Animal procedures
All experiments were approved by The University of Melbourne
Animal Ethics Committee and were conducted in accordance with
the Australian Code of Practice for the Care and Use of Animals
for Scientific Purposes. Wistar Kyoto female rats were housed in
an environmentally controlled room (temperature 22uC) with
a 12 hour light/dark cycle and had access to food and tap water ad
libitum. In a separate cohort to our previously published study at
4 months [12], rats were mated and surgery performed on day 18
of pregnancy (term is 22 days) as described previously [26]. F0
pregnant rats were randomly allocated into a Control (sham
surgery) or Restricted (uteroplacental insufficiency) group. Uter-
oplacental insufficiency was induced by bilateral uterine artery and
vein ligation on day 18 of pregnancy [26]. Sham surgery was
identical except vessels were not ligated. Pregnant rats were
allowed to deliver naturally at term on day 22 of gestation and
birth weights of F1 female offspring were recorded. Uteroplacental
insufficiency reduced total (male and female) litter size but litter
size was not equalised between the groups. We have previously
shown that reducing litter size from sham-operated dams impairs
maternal mammary morphology, lactation and subsequent post-
natal growth and health of the offspring [11,26]. Thus, we do not
regard sham-exposed, culled litters as adequate controls. F1
Control and Restricted females were allocated to one of the 2
study groups, Virgin or Ex-Pregnant (1 per litter/group; n = 12/
group). Those allocated to Ex-Pregnant groups were mated with
a normal male at 17–23 weeks and delivered naturally at term. F1
female body weights were measured at postnatal days 1, 7, 14, 35
and at 4, 6, 9 and 13 months.
Insulin challenge and intraperitoneal glucose tolerance
test
At 12 months, an insulin challenge (IC) and intraperitoneal
glucose tolerance test (IPGTT) were performed a week apart in
females rats after an overnight fast. Blood samples (300 ml) were
taken prior to and following a subcutaneous bolus injection of
insulin (Actrapid, Novo Nordisk Pharmaceuticals, North Rocks,
NSW, Australia; 1 unit/kg body weight) or an intraperitoneal
bolus injection of 50% (wt/vol) glucose (Pharmalab, Lane Cove,
NSW, Australia; 1 g/kg body weight) [7,10]. Plasma was stored at
220uC until further analysis. At completion of the experiment,
animals were allowed access to food and water ad libitum.
Plasma insulin concentrations were measured in duplicate using
a commercially available rat insulin radioimmunoassay kit
(Millipore, Abacus ALS, Brisbane, QLD, Australia) [7,10–12].
Plasma glucose concentrations were measured in duplicate using
a scaled-down version of the enzymatic fluorometric analysis
[7,10–12]. Fasting plasma glucose and insulin was taken as the
average of two time points (10 and 5 min before glucose injection).
Glucose and insulin area under the curve (AUC) were calculated
as the total area under curve from basal to 120 minutes for an
IPGTT and glucose AUC from basal to 60 minutes for an IC.
First phase insulin secretion is indicative of the immediate
pancreatic insulin secretory response to the glucose injection
[27,28] and was calculated as the incremental area under the
insulin curve from basal to 5 minutes [7,10]. Second phase insulin
secretion comprised the remainder of the insulin response and was
calculated as the incremental area under the insulin curve from 5
to 120 minutes [7,10]. Homeostasis model assessment for insulin
resistance (HOMA-IR) was calculated using the following formula:
fasting plasma insulin (m U/ml21) 6 fasting plasma glucose
(mmol/liter21) 4 22.5 [7,10,11,29].
Post mortem tissue
Approximately 2 weeks after IPGTT, non fasted female rats
were anesthetized with an intraperitoneal injection of inactin
(150 mg/kg body weight). Dorsal white adipose tissue, liver and
pancreas were excised and weighed. Liver was snap frozen in
liquid nitrogen and stored at 280uC for glycogen and triacylygly-
cerol analyses. A piece of pancreatic tissue (,1 cm) from the
hepatic end was fixed in 10% neutral buffer formalin for
histological analysis.
Pancreatic islet, b-cell morphology and
immunohistochemistry
Pancreatic tissue was processed, embedded in paraffin wax and
exhaustively sectioned at 5 mm. Three sections of equal distance
apart were selected and immunostained using a guinea pig
polyclonal anti-insulin antibody (1:200 dilution, Dako, King-
sgrove, NSW, Australia) (n = 6/group) [6,7,10]. Pancreatic islet
number and area (per mm2) were averaged across 3 sections with
islet area arbitrarily divided into small (,5000 mm2), medium
(5000–10,000 mm2) and large (.10,000 mm2) [6,7,10,30]. Ran-
dom systematic point counting of 50 fields of view was used to
determine relative islet and b-cell volume density using a 700 point
grid (700 points/field, Vd equals the number of intercepts on an
islet of insulin positive cells as a proportion of intercepts on
a pancreas). Given that 1 cm3 tissue weighs approximately 1g, Vd
and pancreatic weight are multiplied to determine absolute islet
and b-cell mass, expressed in milligrams per gram [6,7,10,12,31].
Terminal transferase-mediated X-dUTP Nick end Labelling
(TUNEL) method with the ApopTag in situ detection kit was used
for determination of b-cell death on sequential pancreas sections
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that had been immunostained for insulin [7]. Apoptic nuclei were
stained in brown with DAB and were counterstained with
haematoxylin to visualise nuclei. Post-weaning (day 4) rat mam-
mary tissue was used as a positive control (Millipore, Abacus ALS,
Brisbane, QLD, Australia).
Liver glycogen and triacylglycerol content
Liver glycogen was extracted from ,15–25 mg powdered liver
into 2 M HCl, then 0.6 M NaOH, and analysed for glucose units
using an enzymatic flurometric method [11,32]. Liver triacylgly-
cerol was extracted from ,15–20 mg powdered liver in CHCl3-
MeOH (2:1 vol/vol), and MgCl2 was added to separate the phases.
The organic extracts were dried down, reconstituted in ethanol,
and assayed for triacylglyerol (total glycerol) by measuring the
glycerol liberated after enzymatic hydrolysis of triacylglycerol
(GPO-PAP, Roche Diagnostics, Castle Hill, NSW, Australia) [33].
Statistical analyses
All data were analysed using a two-way ANOVA to determine
main effects of uteroplacental insufficiency and pregnancy. Two-
way ANOVA with repeated measures was performed for IPGTT
analysis of plasma glucose and insulin concentrations over time. If
a significant interaction was detected, Student’s unpaired t-test was
performed. Data are presented as means6SEM and p,0.05 was
considered statistically significant.
Results
Body and organ weight
Uteroplacental insufficiency in F0 females reduced F1 (male and
female) litter size (5–6 Restricted pups vs. 8–9 Control pups) and
body weight at postnatal day 1 (p,0.05). Restricted females
remained lighter at all ages studied (p,0.05). During pregnancy,
Restricted Ex-Pregnant females gained 21% less weight than
Controls (p,0.05) and by 6 months of age, they were of similar
weight to their Virgin counterparts while Controls remained
heavier (p,0.05, Table 1). Absolute pancreas weight was reduced
in Restricted compared with Control (p,0.05) from both Virgin
and Ex-Pregnant groups, however relative (corrected for body
weight) pancreas weight was not different (Table 1). Absolute and
relative dorsal white adipose tissue and liver weights were not
different across groups (Table 1).
Metabolic parameters
Fasting plasma glucose, insulin and the ratio of fasting insulin to
glucose were not different across groups (Table 2). Restricted Ex-
Pregnant females had reduced fasting insulin levels compared with
their Control counterparts but this did not reach statistical
significance (257%, p=0.065, Table 2). HOMA-IR was reduced
in Restricted females regardless of pregnancy status (p,0.05;
Table 2) indicating enhanced basal hepatic insulin sensitivity.
HOMA-IR was increased after pregnancy compared with Virgin
females, regardless of maternal birth weight which was greater in
Control (+75%) than in Restricted (+59%) (p,0.05, Table 2).
Liver glycogen and triacylglycerol content were not different
between Control and Restricted or between Virgin and Ex-
Pregnant groups (Table 2).
In response to an IPGTT, plasma glucose was not different
between Control and Restricted Virgin females (Fig. 1A & 1C).
Restricted Virgin females secreted less insulin compared with their
Control counterparts during the last hour of the IPGTT indicating
improved insulin sensitivity (Fig. 1D). This was reflected by the
decreased area under insulin curve (AUIC; 236%; p,0.05;
Fig. 1F). Plasma glucose (Fig. 1B & 1C) and insulin (Fig. 1E & 1F)
Table 1. Body and organ weights in Virgin and Ex-Pregnant
females.
Virgin Ex-Pregnant
Control Restricted Control Restricted
Body weight (g)
Postnatal day 1 4.260.1 3.560.1* 4.360.1 3.360.1*
Postnatal day 7 10.460.3 8.160.3* 10.260.4 6.860.4*
Postnatal day 14 23.060.5 19.560.6* 22.460.5 16.761.0*
Postnatal day 35 7662 6662* 7461 6162*
4 months 22264 20863* 21963 20165*
Mating – – 23863 21066*
Delivery – – 27463 23966 *
Pregnancy weight gain – – 3662 2963*
6 months 24763 23963* 27764d 24066*
9 months 26464 25162* 26764 23966*
13 months 28566 27063* 28463 25866*
Organ weight
Pancreas (g) 0.9560.04 0.8760.05* 0.9460.04 0.7860.05*
Pancreas (% body
weight)
0.3660.02 0.3260.05 0.3360.04 0.3060.02
Dorsal white adipose
tissue (g)




1.960.2 2.060.1 1.960.4 1.860.1
Liver (g) 7.760.2 6.960.2 7.760.2 7.460.2
Liver (% body weight) 2.760.1 2.660.04 2.760.1 2.860.1
Values are expressed as means6SEM; n= 10–12/group. * p,0.05 vs. Control
(main effect by two-way ANOVA), d p,0.05 Ex-Pregnant Control vs. Virgin
Control (Student’s t-test following observation of significant interaction).
doi:10.1371/journal.pone.0045188.t001
Table 2. Basal metabolic and liver parameters in Virgin and
Ex-Pregnant females.
Virgin Ex-Pregnant




6.560.3 6.660.2 6.960.3 6.760.3
Fasting insulin
(ng.ml21)
0.4060.04 0.3460.12 0.6560.13 0.3760.06
Fasting insulin:glucose
ratio
0.0660.01 0.0560.01 0.0960.02 0.0660.01
HOMA-IR 2.860.3 1.760.3* 4.961.1# 2.760.6*#
Triacylglycerol
(mmol.g21 liver)




115615 121615 10668 101614
Values are expressed as means6SEM; n= 9–11/group. * p,0.05 vs. Control
(main effect by two-way ANOVA) and # p,0.05 vs. Virgin (main effect by two-
way ANOVA).
doi:10.1371/journal.pone.0045188.t002
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Figure 1. Plasma glucose and insulin response during an IPGTT. Plasma glucose response in Virgin (A), Ex-Pregnant (B), and plasma insulin
response in Virgin (D), Ex-Pregnant (E), glucose area under curve (C), insulin area under curve (F). Values are expressed as means6SEM; n=10/group. c
p,0.05 Virgin Restricted vs. Virgin Control (Student’s t-test following observation of significant interaction) and d p,0.05 Ex-Pregnant Control vs.
Virgin Control (Student’s t-test following observation of significant interaction).
doi:10.1371/journal.pone.0045188.g001
Post Pregnancy Metabolic Disease Risk
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responses were not different between Control and Restricted Ex-
Pregnant females. Control Ex-Pregnant females had reduced
insulin secretion compared with their Virgin counterparts (Fig. 1F).
First phase insulin secretion, represented as insulin AUC from
basal to 5 min, is an indication of b-cell response to glucose during
an IPGTT. This was not different between Control and Restricted
from Virgin and Ex-Pregnant groups (Fig. 2A). Second phase
insulin secretion (insulin AUC from 5 to120 mins), an indirect
measure of peripheral insulin sensitivity, was reduced in Restricted
Virgins compared with Controls (p,0.05) but not different
between groups after pregnancy (Ex-Pregnant; Fig. 2B). The
insulin secretory response to glucose, expressed as the ratio of
AUIC to AUGC, was reduced in Restricted Virgin compared with
Control counterparts (240%, p,0.05; Fig. 2C) and in Control Ex-
Pregnant compared with Control Virgins (245%, p,0.05;
Fig. 2C). Whole body insulin sensitivity, assessed by the glucose
AUC in response to an insulin challenge, was not different across
groups (Fig. 2D).
Pancreatic b-cell and islet morphology and apoptosis
At 13 months, b-cell and islet mass were not different between
Control and Restricted from Virgin and Ex-Pregnant groups
(Fig. 3A & 3B). At 4 months however, b-cell mass was reduced in
Restricted Virgins compared with their Control counterparts
(237%; p,0.05; Fig. 3C) as previously reported [12]. b-cell mass
was increased in Restricted Virgins at 13 months when compared
with Restricted Virgins at 4 months (+48%; p,0.05) but not
different in Controls (Fig. 3C). Total number of islets per section
area was not different but Ex-Pregnant females had fewer small
islets compared with Virgins regardless of birth weight (data not
shown). Ex-Pregnant Controls had a greater percentage of large
islets compared with Virgin Controls (data not shown). There was
no difference in the percentage of medium islets across groups
Figure 2. Plasma insulin secretion and whole body insulin sensitivity. First phase insulin secretion (A), second phase insulin secretion (B)
ratio of AUIC:AUGC (C) and whole body insulin sensitivity (D). Values are expressed as means6SEM; n= 10/group. c p,0.05 Virgin Restricted vs. Virgin
Control (Student’s t-test following observation of significant interaction) and d p,0.05 Ex-Pregnant Control vs. Virgin Control (Student’s t-test
following observation of significant interaction).
doi:10.1371/journal.pone.0045188.g002
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(data not shown). Very few apoptotic nuclei were detected at
13 months, with no changes across groups (data not shown).
Discussion
Despite loss of glucose tolerance during pregnancy at 4 months
of age [12], the present study demonstrates that growth restricted
female rats exhibit mostly normal glucose control later in life at
13 months. Growth restriction was however associated with
enhanced basal hepatic insulin sensitivity (decreased HOMA-IR)
in both Virgin and Ex-Pregnant females. A prior pregnancy was
associated with reduced hepatic insulin sensitivity with effects more
pronounced in Controls than Restricted. This was not associated
with changes in intracellular hepatic lipid levels. The absence of
catch up growth in our growth restricted females may play an
important role in protecting them from adverse metabolic
outcomes in the long term.
Growth profile
Exposure to late gestation uteroplacental insufficiency reduced
F1 male and female day 1 body weights by 17–22% and growth
restricted females remained lighter throughout their entire post-
natal life consistent with our previous experimental studies
[10,11,34]. Early accelerated growth has been demonstrated to
independently predict adult disease risk, such that catch up growth
in early childhood often provides long-lasting benefits, in contrast
to the detrimental effects of a late accelerated growth [35].
Additionally, a mismatch between prenatal and postnatal envir-
onments is also thought to be a major independent contributor to
programmed diseases in adulthood [36]. In the current study,
there were no evidence of accelerated growth or altered body
composition in the postnatal period and this may therefore protect
growth restricted females from adverse metabolic outcomes in the
long term [37]. Other studies have reported that growth restricted
offspring have better glucose tolerance and insulin sensitivity in
young adulthood when their body weight was maintained on
a lower growth trajectory after birth [38,39]. However, the extent
at which a steady postnatal growth trajectory contributes to
enhanced insulin sensitivity remains unknown. During pregnancy,
Restricted females gained 21% less weight than Controls which
may be partly attributable to the reduced food intake observed late
in pregnancy [12] and as such may prevent the development of
obesity that is often associated with low weight at birth [4].
Metabolic profile
Despite the development of impaired glucose tolerance during
late pregnancy at 4 months of age [12], our growth restricted female
rats do not exhibit any long term alterations in metabolic control.
Fasting glucose and insulin, glucose tolerance, pancreatic function
and hepatic glycogen and lipid levels in Restricted were comparable
to normal birth weight Ex-Pregnant females and Virgin counter-
parts. This is likely due to increased estradiol concentrations in our
growth restricted females [40] which may play a protective role
against the development of hyperglycemia [41,42]. Although
plasma glucose levels remained elevated at the final time point of
120 minutes post glucose load in all females, this unexpected delay
to return to baseline glucose levels is likely due to advanced age
compared with our previous study at 4 months. Thus an extended
Figure 3. Pancreatic morphology. b-cell mass (A), islet mass (B) at
13 months and b-cell mass in Virgins only; 4 month* vs. 13 month (C).
Values are expressed as means6SEM; n=6/group. c p,0.05 Virgin
Restricted vs. Virgin Control (Student’s t-test following observation of
significant interaction) and y p,0.05 Virgin Restricted 13 months vs.
Virgin Restricted 4 months (Student’s t-test following observation of
significant interaction). *N.B. Virgin 4 month data reproduced with
permission from Gallo et al. 2012.
doi:10.1371/journal.pone.0045188.g003
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sampling time up to 180 minutes is needed to quantify baseline
glucose values in these older females at 13 months.
Hepatic insulin resistance is considered the major determinant
of fasting hyperglycemia and the current data suggest enhanced
hepatic insulin sensitivity in our growth restricted females. This is
in contrast to a previous study by our group, where non pregnant
growth restricted females had increased HOMA-IR compared
with Controls at 6 months of age [11]. The difference between
studies may be attributed to the greater degree of growth
restriction in the current study and the ages studied; hepatic
insulin sensitivity was reduced in early adulthood (6 months) but
improved by late adulthood at 12 months. During pregnancy,
HOMA-IR was not different between Control and Restricted
females so this improved hepatic insulin sensitivity in Restricted
Ex-Pregnant females at 13 months was manifested after pregnan-
cy. Regardless of birth weight, HOMA-IR was increased after
a pregnancy, suggestive of a mild metabolic defect which may be
risk factor for diabetes [43]. Furthermore, additional challenges
such as obesity may predispose previously pregnant females to
more severe metabolic dysfunction compared with obesity in never
pregnant females. Studies have shown hepatic insulin sensitivity is
inversely proportional to intrahepatic lipid content [44–46] with
increased intrahepatic lipids in low birth weight animals [47]. In
the present study however, we report no differences in triacylgly-
cerol (TAG) content between Control and Restricted nor were
there any prior pregnancy effects. Our results suggest that other
cellular mechanisms in insulin signalling underlie the subtle
changes in basal insulin sensitivity in female rats born small and
after a pregnancy.
In response to an IPGTT, Virgin Restricted females had a lower
glucose stimulated insulin release in the last hour at 60, 90 and
120 minutes that is also indicated by the lower total and second
phase insulin AUC. As second phase insulin secretion represents an
indirect measure of peripheral insulin sensitivity, these findings may
suggest improved skeletal muscle insulin sensitivity in Restricted
Virgin females, given it is responsible for,80% of the body’s insulin
stimulated glucose uptake [48]. Improved insulin sensitivity in
Restricted females was not evident in those who had been previously
pregnant but Ex-Pregnant females had generally lower insulin levels
in response to a glucose load compared with Virgins. Future studies
using insulin stimulated cohort of animals is required to identify
changes in insulin signalling pathway in skeletal muscle. Addition-
ally, whole body insulin sensitivity was not different across groups,
therefore future work using the highly sensitive gold standard
measurement of insulin sensitivity, the hyperinsulinaemic euglyce-
mic clamp technique, combined with tracer methodology may be
useful in simultaneously quantifying hepatic glucose output and
whole body glucose disposal. Under these conditions, one can
distinguish any changes in hepatic and skeletal muscle insulin
sensitivity. Overall, exposure to uteroplacental insufficiency, in the
absence of catch up growth, may prevent the deterioration of in vivo
insulin action that occurs with age and as a result, glucose levels are
more easily maintained.
Pancreatic morphology and function
At 13 months of age, b-cell and islet mass in Restricted females
were comparable to Controls from Virgin and Ex-Pregnant groups.
Pancreatic b-cell mass is positively correlated with glucose
stimulated insulin secretion and these morphological observations
were associated with the unchanged first phase insulin secretory
response. We have previously reported that at 4 months of age,
Virgin Restricted females had reduced b-cell mass and basal insulin
secretion [12], consistent with previous studies [4,5]. During
pregnancy however, b-cell mass increased to compensate for
reduced insulin sensitivity and values were comparable to Controls
[12]. By one week post-partum, b-cell mass returns to pre-pregnant
values via increased apoptosis and reduced proliferation [49].
Although our results suggest that pregnancy in Restricted females
may be associated with sustained b-cell restoration (given that values
were comparable to Controls at 13 months), a sole ageing effect is
more likely given that Virgin Restricted females also exhibited b-cell
restoration between 4 and 13 months of age. However, when the
demand for insulin is greater due to further ageing or a high salt/fat
diet, this will place a higher demand on the pancreatic b-cells and
their compensatory limits will be exhausted and may reveal
impaired metabolic control.
Pancreatic b-cells mass is dynamic and can be up- or down-
regulated in response to changes in metabolic demand to maintain
normoglycemia. With ageing, b-cell mass and insulin secretion
increase to overcome the normal age-related decline in insulin
sensitivity [50,51]. Failure to do so results in loss of glucose
tolerance and diabetes ensues [52,53]. Although b-cell pro-
liferation was not measured in the current study, the b-cell
proportion per islet in Virgin Restricted was not different between
4 and 13 months suggesting that proliferation was unlikely to be
modified in the ageing female. Therefore further studies would
involve analyses of expression of key genes and proteins important
for maintenance of b-cell mass and function, to determine whether
this contributes to restoration of b-cell mass in Restricted Virgin
females compared with Control counterparts at 13 months of age.
In normal birth weight females, the increase in b-cell mass
between 4 and 13 months was small and in fact levels remained
comparable between the ages. This suggests that at 13 months of
age, insulin sensitivity was not overtly compromised and additional
ageing and/or further challenges are required to encourage b-cell
growth in Controls. Indeed, studies in the rat have shown that
from 15 months, b-cell hypertrophy is the predominant mecha-
nism for b-cell mass growth [54].
Conclusion
Our findings indicate that long term glucose control and
pancreatic morphology was normal at 13 months despite pre-
viously reporting impaired glucose tolerance in female rats born
small at 4 months of age. Uteroplacental insufficiency in the
absence of catch-up growth enhanced basal hepatic insulin
sensitivity in female offspring which may provide protection
against adverse metabolic outcomes often associated with being
born small. On the other hand, a prior pregnancy was associated
with a mild metabolic dysfunction where hepatic insulin sensitivity
was reduced. Our data suggests that pregnancy ameliorates the
enhanced peripheral insulin sensitivity in growth restricted females
and has deleterious effects for hepatic insulin sensitivity, regardless
of maternal birth weight. Further investigations will be critical in
determining the underlying mechanisms responsible for these
alterations in hepatic and peripheral insulin sensitivity.
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